← Browse by Condition
Medical Condition

metastatic breast cancer

Total Trials
21
Recruiting Now
21
Trial Phases
Phase 1, Phase 2, Phase 1, Phase 3
NCT06064812 Phase 1, Phase 2
Recruiting

A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.

Enrollment
99 pts
Location
China
Sponsor
Forward Pharmaceuticals Co., L...
View Trial →
NCT04608357
Recruiting

Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients

Enrollment
25 pts
Location
Canada
Sponsor
Sunnybrook Health Sciences Cen...
View Trial →
NCT05900895 Phase 1
Recruiting

Estradiol Plus Olaparib for Breast Cancer (PHOEBE)

Enrollment
6 pts
Location
United States
Sponsor
Mary D Chamberlin
View Trial →
NCT06044623 Phase 3
Recruiting

Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients

Enrollment
495 pts
Location
Finland, Greece, Ita...
Sponsor
Region Örebro County
View Trial →
NCT05349227
Recruiting

Comprehensive Outcomes for After Cancer Health

Enrollment
625 pts
Location
United States
Sponsor
Pack Health
View Trial →
NCT07024173 Phase 3
Recruiting

A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer

Enrollment
240 pts
Location
China
Sponsor
Shandong Suncadia Medicine Co....
View Trial →
NCT02422641 Phase 2
Recruiting

Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

Enrollment
16 pts
Location
United States
Sponsor
Wake Forest University Health ...
View Trial →
NCT05907681
Recruiting

Prospective Observational Study on Outcome of High-precision Hypo-fractionated Radiotherapy in Metastatic Breast Cancer (PRECISE-M)

Enrollment
400 pts
Location
South Korea
Sponsor
Samsung Medical Center
View Trial →
NCT05894239 Phase 3
Recruiting

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Enrollment
230 pts
Location
United States, Argen...
Sponsor
Hoffmann-La Roche
View Trial →
NCT02102165
Recruiting

AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.

Enrollment
1,000 pts
Location
Belgium, Germany, Ic...
Sponsor
Breast International Group
View Trial →
NCT07347600
Recruiting

A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

Enrollment
500 pts
Location
China
Sponsor
Hoffmann-La Roche
View Trial →
NCT05440929
Recruiting

Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians

Enrollment
15 pts
Location
United States
Sponsor
UNC Lineberger Comprehensive C...
View Trial →
NCT05732051 Phase 2
Recruiting

Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients

Enrollment
60 pts
Location
Norway
Sponsor
University Hospital, Akershus
View Trial →
NCT06827236 Phase 1, Phase 2
Recruiting

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Enrollment
380 pts
Location
United States, Canad...
Sponsor
BioNTech SE
View Trial →
NCT06388122
Recruiting

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients

Enrollment
100 pts
Location
United States
Sponsor
Mayo Clinic
View Trial →
NCT06991946
Recruiting

Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in Spain

Enrollment
300 pts
Location
Spain
Sponsor
SOLTI Breast Cancer Research G...
View Trial →
NCT07002177 Phase 1, Phase 2
Recruiting

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Enrollment
196 pts
Location
China
Sponsor
Forward Pharmaceuticals Co., L...
View Trial →
NCT06409390 Phase 2
Recruiting

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Enrollment
15 pts
Location
United States
Sponsor
H. Lee Moffitt Cancer Center a...
View Trial →
NCT06877949
Recruiting

FDG-PET/CT vs. CT for Monitoring Metastatic Breast Cancer

Enrollment
420 pts
Location
Denmark, Germany, It...
Sponsor
Odense University Hospital
View Trial →
NCT03591276 Phase 1, Phase 2
Recruiting

Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer

Enrollment
15 pts
Location
Israel
Sponsor
Shaare Zedek Medical Center
View Trial →
NCT05720260 Phase 2
Recruiting

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

Enrollment
42 pts
Location
Taiwan
Sponsor
National Taiwan University Hos...
View Trial →